Cutler Group’s Meridian Bioscience Inc VIVO Stock Holding History

Cutler Group’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,000	Closed	-$14.4K	–	7331
2017 Q1	$13K	Buy	+1,000	New	+$14K	﹤0.01%	3814
2016 Q4	–	Sell	-905	Closed	-$15.9K	–	7559
2016 Q3	$17K	Hold	905	–	–	﹤0.01%	3617
2016 Q2	$17K	Sell	905 -100	-10%	-$1.96K	﹤0.01%	3557
2016 Q1	$20K	Sell	1,005 -1,382	-58%	-$27.2K	﹤0.01%	3307
2015 Q4	$48K	Buy	+2,387	New	+$45.8K	﹤0.01%	2509

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cutler Group's VIVO Position: Q2 2017 in Review

Cutler Group sold out of Meridian Bioscience Inc (VIVO) in Q2 2017, closing a stake of 1,000 shares — an estimated $14.4K sold.

Cutler Group first reported a position in VIVO in Q4 2015 and held it in 5 quarters. The position peaked at $48K in Q4 2015. 170 funds tracked by Wall St. Rank hold VIVO as of Q2 2017.

Cutler Group reported no remaining Meridian Bioscience Inc position as of Q2 2017 after selling out during the quarter.
Cutler Group sold 1,000 Meridian Bioscience Inc shares in Q2 2017, an estimated $14.4K.
Cutler Group first reported a position in Meridian Bioscience Inc in Q4 2015 and held it in 5 quarters.
Cutler Group's Meridian Bioscience Inc position peaked at $48K in Q4 2015.
170 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2017.

Based on Cutler Group's 13F filing for Q2 2017, filed 11 Jul 2017.